Skip to main content
Premium Trial:

Request an Annual Quote

Strategic Diagnostics' Q2 Revenues Rise 5 Percent

NEW YORK (GenomeWeb news) – Strategic Diagnostics reported after the close of the market on Thursday that its second-quarter revenues increased 5 percent, and the firm cuts its net loss around 3 percent year over year.

The Newark, Del.-based firm brought in revenues of $6.9 million for the three-month period ended June 30, compared to revenues of $6.6 million for the second quarter of 2008. The company said that its revenues were positively impacted by a 16 percent increase in life science revenues and a 45 percent increase in sales of its Genomic Antibody Technology products.

Strategic Diagnostics trimmed its Q2 net loss to $734,000, or $.04 per share, from $1.1 million, or $.05 per share.

Its R&D spending decreased to $820,000 from $921,000, while its SG&A costs was trimmed to $3.5 million from $4.1 million.

Strategic Diagnostics finished the quarter with $6.2 million in cash and cash equivalents, plus $2.7 million in restricted cash.

Filed under

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.